Glutethimide

Summary

Glutethimide (CHEMBL1102) is an approved small molecule (ATC N05CE01).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CE01
• Chemistry: 217.26 Da · C13H15NO2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1102
Name	Glutethimide
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3487
ATC	N05CE01
Molecular formula	C13H15NO2
Molecular weight	217.26
InChIKey	JMBQKKAJIKAWKF-UHFFFAOYSA-N

SMILES: CCC1(CCC(=O)NC1=O)C2=CC=CC=C2

IUPAC name: 3-ethyl-3-phenylpiperidine-2,6-dione

Also known as: Doriden, Elrodorm, Glutethimide, Glutetimida, Noxyron, NSC-95239, Rigenox, Sarodormin, GLUTETHIMIDE, SID29215340, SID144205194, SID170465223

Patent coverage: 2,138 distinct patent families (7,788 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).